Minerva Neurosciences, Inc. — fact timeline

Minerva Neurosciences, Inc. shareholders approved Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“Proposal 6: Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. The voting results were as follows: For Against Abstain Broker Non-Votes 35,289,299 7,131 1,092 —”

Minerva Neurosciences, Inc. shareholders approved Approval, on an Advisory Basis, of the Frequency of Solicitation of Future Advisory Stockholder Approval of Named Executive Officer Compensation at the 2026-06-03 meeting.

“Proposal 5: Approval, on an Advisory Basis, of the Frequency of Solicitation of Future Advisory Stockholder Approval of Named Executive Officer Compensation. The Company’s stockholders approved Proposal 5. The voting results were as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 30,365,516 1,639 9,934 16,200 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-06-03 meeting.

“Proposal 4: Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers, as disclosed in the Proxy Statement. The Company’s stockholders approved Proposal 4. The voting results were as follows: For Against Abstain Broker Non-Votes 27,183,828 3,196,678 12,783 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Eliminate the Exclusive Forum Provision at the 2026-06-03 meeting.

“Proposal 3: Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Eliminate the Exclusive Forum Provision. The Company’s stockholders approved Proposal 3. The voting results were as follows: For Against Abstain Broker Non-Votes 30,360,809 20,954 11,526 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Reflect Delaware Law Provisions Allowing for the Exculpation of Certain Officers at the 2026-06-03 meeting.

“Proposal 2: Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Reflect Delaware Law Provisions Allowing for the Exculpation of Certain Officers. The Company’s stockholders approved Proposal 2. The voting results were as follows: For Against Abstain Broker Non-Votes 27,222,961 3,169,756 572 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Election of Directors at the 2026-06-03 meeting.

“Proposal 1: Election of Directors. Two nominees were elected to serve on the Board until the Company’s 2029 annual meeting of stockholders and until their successors are elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Dr. David Kupfer 23,211,099 7,182,190 4,904,233 Jan van Heek 30,369,333 23,956 4,904,233”

Minerva Neurosciences, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $75.0 million (effective 2026-05-27).

“On May 27, 2026, Minerva Neurosciences, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Agent”) with respect to an “at-the market” offering program, pursuant to which the Company may issue and sell, from time to time, shares of its common stock, par value $0.0001 per share (“Common Stock”).”

Minerva Neurosciences, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $125.4 million, or $2.86 per basic and diluted share, EPS $2.86 per basic and diluted share.

“today reported financial and business updates for the first quarter ended March 31, 2026.”

Minerva Neurosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

“Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended December 31, 2025.”

Minerva Neurosciences, Inc. issued tranche A warrants to acquire shares of Series A Preferred Stock and tranche B warrants to acquire shares of Series A Preferred Stock of warrant to certain accredited investors for Exercise price $1,000 per share, aggregate cash exercise price up to $80 million for Tranche A and $40 million for Tranche B.

“placement (the “Private Placement”), (i) 80,000 shares of Series A Convertible Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”), at a purchase price of $1,000 per share, (ii) tranche A warrants (the “Preferred Tranche A Warrants”) to acquire shares of Series A Preferred Stock (the “Tranche A Warrant Shares”) and (iii) tranche B warrants”

Minerva Neurosciences, Inc. issued 80,000 shares of Series A Convertible Preferred Stock of preferred stock to certain accredited investors for $1,000 per share.

“The Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) 80,000 shares of Series A Convertible Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”), at a purchase price of $1,000 per share”

Minerva Neurosciences, Inc.: The Company filed a Certificate of Designation designating 200,000 shares of authorized preferred stock as Series A Convertible Voting Preferred Stock (effective 2025-10-21).

“on October 21, 2025, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware, designating 200,000 shares of its authorized and unissued preferred stock as Series A Preferred Stock”

Jeryl Hilleman resigned as Director and Chair of the Audit Committee at Minerva Neurosciences, Inc..

“On May 29, 2024, Jeryl Hilleman notified the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) of her intention to resign as a member of the Board, effective August 6, 2024, including from her role as Chair of the Audit Committee of the Board.”

Minerva Neurosciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“April 10, 2024, Minerva Neurosciences, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities (the “MVLS requirement”) for the Company’s common stock had been below the minimum MVLS requirement of $35,000,000 for the last 31 consecutive business days. The notification of noncompliance indicated that the Company would be provided 180 calendar days in which to regain compliance with the MVLS requirement. The Notice provides the Company wi”

Minerva Neurosciences, Inc. shareholders approved Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 at the 2023-09-27 meeting.

“Proposal 4: Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 . The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified with the votes set forth below: For Against Abstain Broker Non-Votes 5,061,117 11,600 234,283 0”

Minerva Neurosciences, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2023-09-27 meeting.

“Proposal 3: Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers . The Company’s stockholders approved Proposal 3. The votes cast were as follows: For Against Abstain Broker Non-Votes 3,738,851 71,469 53,727 1,442,953”

Minerva Neurosciences, Inc. shareholders approved Approval of Amendment to the Company’s Amended and Restated 2013 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 700,000 shares at the 2023-09-27 meeting.

“Proposal 2: Approval of Amendment to the Company’s Amended and Restated 2013 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 700,000 shares. The Company’s stockholders approved Proposal 2. The votes cast were as follows: For Against Abstain Broker Non-Votes 3,283,310 576,673 4,064 1,442,953”

Minerva Neurosciences, Inc. shareholders approved Election of Directors at the 2023-09-27 meeting.

“The results of matters submitted to a stockholder vote at the Annual Meeting of Stockholders of Minerva Neurosciences, Inc. (the “Company”) held on September 27, 2023 (the “2023 Annual Meeting”) are as follows: Proposal 1: Election of Directors . Two nominees were elected to serve on the Company’s Board of Directors until the 2026 annual meeting of stockholders and until their successors are elected and qualified with the votes set forth below: Nominee For Withheld Broker Non-Votes David Kupfer 3,247,154 616,893 1,442,953 Jan van Heek 3,374,837 489,210 1,442,953”

Minerva Neurosciences, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $20.0 million (effective 2023-06-27).

“On June 27, 2023, Minerva Neurosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 1,425,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a purchase price of $10.00 per Share, and (ii) in lieu of additional shares of Common Stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 575,575 shares of Common Stock at a purchase price of $9.99 per Pre-Funded Warrant.”

Minerva Neurosciences, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“May 31, 2023, the Company received a second written notice from Nasdaq indicating that, based upon the Company’s continued non-compliance with the Rule, the staff of Nasdaq had determined to delist the Company’s securities from The Nasdaq Capital Market unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”). As a result, the Company intends to timely request a hearing before the Panel. The hearing request will stay any suspension or delisting action pending the completion of the hearing and the expiration of any additional extension period granted by the Pane”

William Doyle resigned as Director at Minerva Neurosciences, Inc..

“On May 3, 2023, William Doyle notified the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) of his intention to resign as a member of the Board, effective May 3, 2023, including from his role as Chair of the Compensation Committee of the Board and a member of the Audit Committee of the Board.”

Minerva Neurosciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“December 1, 2022, Minerva Neurosciences, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until May 30, 2023, to regain compliance. The letter states that the Nasdaq”

Frederick Ahlholm was appointed as Chief Financial Officer at Minerva Neurosciences, Inc..

“On October 11, 2021, the Company announced the appointment of Frederick Ahlholm as the Company’s Chief Financial Officer (principal financial officer and principal accounting officer), effective October 11, 2021.”

Geoffrey Race was appointed as President at Minerva Neurosciences, Inc..

“On October 11, 2021, Minerva Neurosciences, Inc. (the “Company”) announced the appointment of Geoffrey Race as the Company’s President, effective October 11, 2021.”